» Articles » PMID: 29084742

Population Pharmacokinetics of Trimethoprim-Sulfamethoxazole in Infants and Children

Abstract

Trimethoprim (TMP)-sulfamethoxazole (SMX) is used to treat various types of infections, including community-acquired methicillin-resistant (CA-MRSA) and infections in children. Pharmacokinetic (PK) data for infants and children are limited, and the optimal dosing is not known. We performed a multicenter, prospective PK study of TMP-SMX in infants and children. Separate population PK models were developed for TMP and SMX administered by the enteral route using nonlinear mixed-effects modeling. Optimal dosing was determined on the basis of the matching adult TMP exposure and attainment of the surrogate pharmacodynamic (PD) target for efficacy, a free TMP concentration above the MIC over 50% of the dosing interval. Data for a total of 153 subjects (240 samples for PK analysis) with a median postnatal age of 8 years (range, 0.1 to 20 years) contributed to the analysis for both drugs. A one-compartment model with first-order absorption and elimination characterized the TMP and SMX PK data well. Weight was included in the base model for clearance (CL/) and volume of distribution (/). Both TMP and SMX CL/ increased with age. In addition, TMP and SMX CL/ were inversely related to the serum creatinine and albumin concentrations, respectively. The exposure achieved in children after oral administration of TMP-SMX at 8/40 mg/kg of body weight/day divided into administration every 12 h matched the exposure achieved in adults after administration of TMP-SMX at 320/1,600 mg/day divided into administration every 12 h and achieved the PD target for bacteria with an MIC of 0.5 mg/liter in >90% of infants and children. The exposure achieved in children after oral administration of TMP-SMX at 12/60 and 15/75 mg/kg/day divided into administration every 12 h matched the exposure achieved in adults after administration of TMP-SMX at 640/3,200 mg/day divided into administration every 12 h in subjects 6 to <21 years and 0 to <6 years of age, respectively, and was optimal for bacteria with an MIC of up to 1 mg/liter.

Citing Articles

Impact of lactoferrin supplementation on cotrimoxazole pharmacokinetics: A preliminary clinical investigation.

Notario D, Munzir A, Novella Y, Hananta L ADMET DMPK. 2024; 12(3):543-551.

PMID: 39091903 PMC: 11289514. DOI: 10.5599/admet.2358.


Challenges for global antibiotic regimen planning and establishing antimicrobial resistance targets: implications for the WHO Essential Medicines List and AWaRe antibiotic book dosing.

Reza N, Gerada A, Stott K, Howard A, Sharland M, Hope W Clin Microbiol Rev. 2024; 37(2):e0013923.

PMID: 38436564 PMC: 11324030. DOI: 10.1128/cmr.00139-23.


Selective and Concentrative Enteropancreatic Recirculation of Antibiotics by Pigs.

Buddington K, Pierzynowski S, Holmes W, Buddington R Antibiotics (Basel). 2024; 13(1).

PMID: 38275322 PMC: 10812520. DOI: 10.3390/antibiotics13010012.


Oral Antibiotics for Bacteremia and Infective Endocarditis: Current Evidence and Future Perspectives.

Eleftheriotis G, Marangos M, Lagadinou M, Bhagani S, Assimakopoulos S Microorganisms. 2023; 11(12).

PMID: 38138148 PMC: 10745436. DOI: 10.3390/microorganisms11123004.


Developmental Pharmacokinetics of Antibiotics Used in Neonatal ICU: Focus on Preterm Infants.

Butranova O, Ushkalova E, Zyryanov S, Chenkurov M Biomedicines. 2023; 11(3).

PMID: 36979919 PMC: 10046592. DOI: 10.3390/biomedicines11030940.


References
1.
Keizer R, van Benten M, Beijnen J, Schellens J, Huitema A . Piraña and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2010; 101(1):72-9. DOI: 10.1016/j.cmpb.2010.04.018. View

2.
Mendes R, Moet G, Janechek M, Jones R . In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates. Antimicrob Agents Chemother. 2010; 54(6):2704-6. PMC: 2876412. DOI: 10.1128/AAC.00301-10. View

3.
Keizer R, Jansen R, Rosing H, Thijssen B, Beijnen J, Schellens J . Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacol Res Perspect. 2015; 3(2):e00131. PMC: 4448983. DOI: 10.1002/prp2.131. View

4.
Stevens R, Laizure S, SANDERS P, Stein D . Multiple-dose pharmacokinetics of 12 milligrams of trimethoprim and 60 milligrams of sulfamethoxazole per kilogram of body weight per day in healthy volunteers. Antimicrob Agents Chemother. 1993; 37(3):448-52. PMC: 187691. DOI: 10.1128/AAC.37.3.448. View

5.
Kagaya H, Miura M, Niioka T, Saito M, Numakura K, Habuchi T . Influence of NAT2 polymorphisms on sulfamethoxazole pharmacokinetics in renal transplant recipients. Antimicrob Agents Chemother. 2011; 56(2):825-9. PMC: 3264276. DOI: 10.1128/AAC.05037-11. View